Contribution of CB1 blockade to the management of high-risk abdominal obesity. - Wikidata - wikimedia - TriplyDB

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

http://www.wikidata.org/entity/Q36434450

about

Differential screening identifies transcripts with depot-dependent expression in white adipose tissues.Mood, food, and obesity.Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.Replication of obesity and diabetes-related SNP associations in individuals from Yucatán, México.The burden of type 2 diabetes: strategies to prevent or delay onset Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility.Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.Emerging strategies for exploiting cannabinoid receptor agonists as medicines.The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients.Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice.

P2860

Q33362562-D3CC30F9-E5E6-45CC-865C-2C9AE733407F Q34113945-1DFDDEAD-CEC7-425E-AEB5-673AFFBDADFE Q34453695-7CB8F692-7D34-4664-9F34-D73B58A12DC3 Q34531657-B10CD80F-617A-4605-8181-2CD9CAAB22D5 Q36536251-FD57AA1A-3CEA-466E-A589-2AC5C6D70386 Q36721060-4A379CD5-2392-4456-94CA-D5559AABEB17 Q37164807-DFF1AEA0-9F34-421D-BD29-4E186DFA837B Q37230665-26322CE1-F7E6-42EF-B35A-2ABE19B25C71 Q38974424-4E67496C-156E-4B79-B99B-57E3A7038F40 Q47797514-EB0AB619-D8F4-4AC0-A6B2-ECD0AFC11DD6 Q50165373-7BB816FA-198C-468F-9ACB-82543944FA03 Q55049564-B9557A77-5A0B-4D5C-A5F4-1D576AA76EEA

P2860

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

http://www.wikidata.org/entity/Q36434450

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

@ast

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

@en

type

label

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

@ast

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

@en

prefLabel

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

@ast

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

@en

P1433

Q36434450-5B3E8AE2-913F-4441-B786-CF53BA42AE56

P1476

Q36434450-73A901AE-0AE2-47CB-ADBF-B2C5AE1932A6

P2093

Q36434450-3A4F67F6-D005-44EB-B805-F907B08D4EE0

Q36434450-940A44CB-56FE-43C4-8CA5-BD9F09BF2660

Q36434450-B7423090-6FDE-47B4-BAD3-FE87B3A7031F

P2860

Q36434450-0A8D7E96-3EB2-421D-BB4D-63153A931FBF

Q36434450-0AAA4736-F081-454A-8974-FD232884F7D8

Q36434450-0F28904C-9864-4F75-9E72-FADA2D57E01C

Q36434450-1122A43B-068C-4199-8D54-06A06AB3F3E9

Q36434450-1179406B-500E-45AF-B27D-89D8A3280BBA

Q36434450-16CF4789-A0AD-4F19-96B0-4AB0B9996EBA

Q36434450-18A5245D-0826-4976-8736-93F119CADEF7

Q36434450-1C719D5B-865D-44DA-88D2-4C6D1904C89F

Q36434450-1FEB961C-7E7E-47A8-A8F4-025853481F31

Q36434450-282C82ED-5B49-403D-9A18-DCC1A17054C0

P2888

Q36434450-53F90623-FD73-4AE9-922D-7AE514E0687B

P304

Q36434450-D1A84487-9D24-4212-92B1-66EE24DB253C

P31

Q36434450-1CE86A85-696C-4962-A485-620B0DA6F6A0

P356

Q36434450-79398C05-5B97-49BF-9EBE-04BC41E882A4

P407

Q36434450-DC6BC2ED-413E-446C-91B5-B7AF5DDA3061

P478

Q36434450-8D1B68DF-3894-481F-8116-C793257D2C92

P577

Q36434450-F9C96106-7438-4F0F-93B9-0058E347F75B

P5875

Q36434450-87708904-3CF9-4ABF-B7AB-BD710990B833

P6179

Q36434450-9C431E54-AE73-4D1B-87CE-FAF6A1522314

P698

Q36434450-A84A36C5-3310-4E21-856E-C95ABDD9AFAA

P921

Q36434450-9817C7E8-0509-4497-BF93-F46D233596AE

P356

P1433

International Journal of Obesity

P1476

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

@en

P2093

I Lemieux

http://www.w3.org/2001/XMLSchema#string

J-P Després

http://www.w3.org/2001/XMLSchema#string

N Alméras

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

Leptin-regulated endocannabinoids are involved in maintaining food intake

2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

The metabolic syndrome--a new worldwide definition

Inflammation and atherosclerosis

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

P2888

P304

S44-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.IJO.0803278

http://www.w3.org/2001/XMLSchema#string

P407

P478

30 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7209404

http://www.w3.org/2001/XMLSchema#string

P6179

1047491498

http://www.w3.org/2001/XMLSchema#string

P698

16570106

http://www.w3.org/2001/XMLSchema#string

P921